Osaic Holdings’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-48
| Closed | -$10.6K | – | 7847 |
|
|
2025
Q4 | $10.6K | Sell |
48
-72
| -60% | -$11.6K | ﹤0.01% | 6316 |
|
|
2025
Q3 | $11.4K | Buy |
+120
| New | +$7.66K | ﹤0.01% | 6282 |
|
|
2024
Q2 | – | Sell |
-2,632
| Closed | -$48.4K | – | 7429 |
|
|
2024
Q1 | $48.4K | Hold |
2,632
| – | – | ﹤0.01% | 4772 |
|
|
2023
Q4 | $41.8K | Hold |
2,632
| – | – | ﹤0.01% | 5019 |
|
|
2023
Q3 | $49.6K | Buy |
2,632
+38
| +1% | +$746 | ﹤0.01% | 5011 |
|
|
2023
Q2 | $58.6K | Buy |
2,594
+649
| +33% | +$15.3K | ﹤0.01% | 4832 |
|
|
2023
Q1 | $49.4K | Buy |
+1,945
| New | +$55.2K | ﹤0.01% | 4961 |
|
|
2022
Q4 | – | Sell |
-1,100
| Closed | -$14K | – | 7199 |
|
|
2022
Q3 | $14K | Hold |
1,100
| – | – | ﹤0.01% | 5820 |
|
|
2022
Q2 | $11K | Hold |
1,100
| – | – | ﹤0.01% | 6008 |
|
|
2022
Q1 | $18K | Sell |
1,100
-5
| -0.5% | -$85 | ﹤0.01% | 5753 |
|
|
2021
Q4 | $28K | Buy |
1,105
+605
| +121% | +$18.8K | ﹤0.01% | 5552 |
|
|
2021
Q3 | $22K | Hold |
500
| – | – | ﹤0.01% | 5695 |
|
|
2021
Q2 | $20K | Buy |
+500
| New | +$21.2K | ﹤0.01% | 5653 |
|
|
2021
Q1 | – | Sell |
-615
| Closed | -$25K | – | 6810 |
|
|
2020
Q4 | $25K | Hold |
615
| – | – | ﹤0.01% | 5009 |
|
|
2020
Q3 | $35K | Hold |
615
| – | – | ﹤0.01% | 4554 |
|
|
2020
Q2 | $45K | Buy |
+615
| New | +$39.9K | ﹤0.01% | 4259 |
|
Osaic Holdings's CDTX Position: Q1 2026 in Review
Osaic Holdings sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 48 shares — an estimated $10.6K sold.
Osaic Holdings first reported a position in CDTX in Q2 2020 and held it in 16 quarters. The position peaked at $58.6K in Q2 2023. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Osaic Holdings reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Osaic Holdings sold 48 Cidara Therapeutics shares in Q1 2026, an estimated $10.6K.
- Osaic Holdings first reported a position in Cidara Therapeutics in Q2 2020 and held it in 16 quarters.
- Osaic Holdings's Cidara Therapeutics position peaked at $58.6K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.